Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant bevacizumab in triple negative breast cancer
jRCT2080220555Phase 3
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
bevacizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCT2080220555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220555.